Volume 12, Issue 2, Pages (August 2005)

Slides:



Advertisements
Similar presentations
Volume 10, Issue 2, Pages (August 2004)
Advertisements

Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 9, Pages (September 2009)
Volume 8, Issue 2, Pages (August 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Induction of Autoimmunity in a Bleomycin-Induced Murine Model of Experimental Systemic Sclerosis: An Important Role for CD4+ T Cells  Hideaki Ishikawa,
Volume 130, Issue 2, Pages (February 2006)
Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII  Brian A. Karolewski,
Volume 15, Issue 1, Pages (January 2007)
Volume 8, Issue 5, Pages (May 2017)
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Evolving Gene Therapy in Primary Immunodeficiency
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Volume 26, Issue 2, Pages (February 2018)
Activation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by AAV Gene Transfer Protects Retinal Ganglion Cells in Glaucoma  Yu Zhou, Vincent.
Volume 9, Issue 2, Pages (February 2004)
Volume 11, Issue 5, Pages (November 1999)
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization  Tae Kwann Park, Si.
Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice  Zhi-Ming.
Volume 13, Issue 1, Pages (January 2006)
Volume 25, Issue 8, Pages (August 2017)
Volume 4, Issue 6, Pages (December 2001)
Volume 10, Issue 6, Pages (December 2004)
Choroidal neovascularization in transgenic mice expressing prokineticin 1: an animal model for age-related macular degeneration  Nobushige Tanaka, Masahito.
Volume 13, Issue 2, Pages (February 2006)
Volume 26, Issue 1, Pages (January 2018)
Volume 18, Issue 2, Pages (February 2010)
Volume 17, Issue 2, Pages (February 2009)
Volume 4, Issue 5, Pages (November 2001)
Molecular Therapy - Methods & Clinical Development
Volume 3, Issue 4, Pages (April 2001)
Volume 2, Issue 4, Pages (October 2000)
Volume 23, Issue 10, Pages (October 2015)
Volume 18, Issue 1, Pages (January 2010)
J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell 
Volume 12, Issue 5, Pages (November 2005)
Volume 12, Issue 2, Pages (August 2005)
Volume 12, Issue 5, Pages (November 2005)
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 1, Pages (January 2017)
Molecular Therapy - Methods & Clinical Development
Hsp70 Gene Transfer by Adeno-associated Virus Inhibits MPTP-Induced Nigrostriatal Degeneration in the Mouse Model of Parkinson Disease  Zhizhong Dong,
Volume 20, Issue 5, Pages (May 2012)
Volume 19, Issue 7, Pages (July 2011)
Volume 12, Issue 2, Pages (August 2005)
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Volume 10, Issue 6, Pages (December 2004)
Volume 13, Issue 1, Pages (January 2006)
Volume 8, Issue 2, Pages (August 2003)
Volume 12, Issue 5, Pages (November 2005)
Volume 26, Issue 2, Pages (February 2018)
J.M.I. Malik, Z. Shevtsova, M. Bähr, S. Kügler  Molecular Therapy 
Volume 17, Issue 10, Pages (October 2009)
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
No defect in T-cell priming, secondary response, or tolerance induction in response to inhaled antigens in Fms-like tyrosine kinase 3 ligand–deficient.
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Volume 9, Issue 3, Pages (March 2004)
Volume 8, Issue 2, Pages (August 2003)
Volume 25, Issue 4, Pages (April 2017)
Volume 6, Issue 5, Pages (November 2002)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Molecular Therapy - Oncolytics
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Tatiana Zavorotinskaya, Adrian Tomkinson, John E Murphy 
Volume 9, Issue 2, Pages (February 2004)
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
Volume 12, Issue 5, Pages (November 2005)
Engraftment of Bone Marrow–derived Stem Cells to the Lung in a Model of Acute Respiratory Infection by Pseudomonas aeruginosa  Joanna Rejman, Carla Colombo,
Presentation transcript:

Volume 12, Issue 2, Pages 369-373 (August 2005) Local Administration of an Adeno-associated Viral Vector Expressing IL-10 Reduces Monocyte Infiltration and Subsequent Photoreceptor Damage during Experimental Autoimmune Uveitis  Cathryn A. Broderick, Alexander J. Smith, Kam S. Balaggan, Anastasios Georgarias, Prateek K. Buch, Peter C. Trittibach, Susie E. Barker, Gian-Marco Sarra, Adrian J. Thrasher, Andrew D. Dick, Robin R. Ali  Molecular Therapy  Volume 12, Issue 2, Pages 369-373 (August 2005) DOI: 10.1016/j.ymthe.2005.03.018 Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

Fig. 1 Murine IL-10 cDNA was purchased from Invivogen (UK) and subcloned between the CMV promoter and the IRES region of the AAV.cmv.CNTF.ires.eGFP construct following removal of the CNTF cDNA to generate the construct pd10.cmv.IL-10.ires.eGFP. The constructs were used to generate recombinant rAAV as previously described [24,25]. Antigen-specific splenocytes were isolated from immunized mice 14 days post-subcutaneous administration and rechallenged in vitro for 48 h. Test wells contained AAV.IL-10 conditioned medium. The biological function of the IL-10 transgene was confirmed by the ability of conditioned medium to decrease (A) antigen-specific lymphocyte proliferation as determined by[3H]thymidine uptake and (B) CD11b+ myeloid cell expression of MHC class II and CD86 costimulatory molecules as detected by flow cytometry. These decreases were negated by an IL-10 neutralizing antibody and are not observed in control vector conditioned medium-treated cells (unpaired Student’s t test, mean ± SD). Molecular Therapy 2005 12, 369-373DOI: (10.1016/j.ymthe.2005.03.018) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

Fig. 2 Subretinal administration of vectors was performed in anesthetized 3- to 4-week-old female C57BL/6 mice (n = 15, Harlan UK Ltd.), under direct retinoscopy through an operating microscope as previously described [26]. A 1.5-cm 34-gauge hypodermic needle (Hamilton, UK) was used to inject 2 μl of virus suspension (genomic titer of 1010 particles/ml) into the subretinal space to produce a bullous retinal detachment in the superior hemisphere and a second in the inferior hemisphere. Where required, left eyes were injected with PBS or titer-matched AAV.GFP as internal controls. Retinal vessels remained patent during and following the injections. All animals received chloramphenicol 1% eye ointment to the cornea. EAU was induced in the AAV-injected group (n = 15) and a control group of 7- to 8-week-old female C57BL/6 mice (n = 6) by injection of 500 μg of IRBP peptide 1–20 (SigmaGenosys, UK) v/v CFA with 2.5 mg/ml M. tub (Sigma, UK) and 1.5 μg pertussis toxin (Sigma) intraperitoneally per mouse in total volumes of 100 μl, as previously described [27]. At 23 days post-EAU, eyes were graded for clinical severity [28]. (A) Normal retinal section grade 0. (B) Disease of grade 2 with vasculitis and retinal infiltration but no photoreceptor loss. (C) Severe disease grade 5 with typical features of granuloma (*), retinal folds (small arrow), loss of photoreceptor layer (arrowhead), and infiltration throughout the retinal layers; notice the retinal thickening compared to (B). H&E sections from AAV.GFP-injected eyes showing (D) extensive retinal infiltration (bar) and (F) vasculitis (*) and choroiditis (arrowhead). (E and G) H&E sections from AAV.IL-10-injected eyes with reduced EAU features. Within the AAV.IL-10 group, there was little photoreceptor layer infiltration or damage. (H) CD45-positive cells are found throughout the AAV.GFP retinal layers (small arrows). (I) In AAV.IL-10-treated eyes CD45-positive cells are rarely detected within the photoreceptor layer. Acetone-fixed retinal sections from AAV.IL-10-treated and AAV.GFP control eyes were stained for expression of nitrotyrosine (1:100, rabbit anti-nitrotyrosine; Upstate Ltd., UK). Primary antibody was detected with goat anti-rabbit: Alexa 594 (Molecular Probes, UK) and sections were counterstained with DAPI (Molecular Probes). Intense levels of positivity were detected (J) within the photoreceptor layer (arrow), (L) in areas of vasculitis, and (N) on cells present in the vitreous (small arrows) within eyes injected with AAV.GFP as expected during EAU. Much reduced levels of nitrotyrosine were detected in corresponding areas of infiltration of AAV.IL-10-injected retina: (K) photoreceptor layer with some infiltrate, (M) no nitrotyrosine by area of vasculitis, some photoreceptor positivity, and (O) very low expression on rare intravitreal cells (small arrows). Original magnifications: A, ×40; B and C, ×20; D–I, ×10; J and K, ×20; M, ×10; L, N, and O, ×40. Molecular Therapy 2005 12, 369-373DOI: (10.1016/j.ymthe.2005.03.018) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions